vTv Therapeutics Inc (VTVT)

vTv Therapeutics Inc (VTVT) is a Biotechnology company in the Healthcare sector listed on the NASDAQ.

As of Oct 23, 2026: market cap $119M; returns 1 day -5.9%, 1 week -3.7%, 1 year +22.6%.

vTv Therapeutics Inc. is a late-stage biopharmaceutical company focused on developing oral, small molecule drug candidates for chronic diseases, particularly diabetes. Their primary focus is on cadisegliatin, a potential first-in-class oral glucokinase activator, currently in Phase 3 trials for the treatment of type 1 diabetes (T1D).

Groups VTVT belongs to

• Type 1 Diabetes
• Biotechnology
• Clinical Stage Biotech
• Biopharmaceutical
• Healthcare
• Pharmaceuticals
• Clinical Stage
• Metabolic Disorders

VTVT financial model: income statement, cash flow and balance sheet